Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[EX Q]: Paragraph: Mentions cost for one year of Herceptin as $40,000-$50,000. Mentions quantitative benefit of 9 weeks of Herceptin vs. no Herceptin with certain chemotherapy. Also, while no women in the Herceptin group had cardiac failure at 3 years, the follow-up period may not be long-enough to determine the effects of chemotherapy and Herceptin on the heart. Mentions potential harms of Herceptin on the heart, especially when given after certain chemotherapy. The story does not mention that there were side effects with certain chemotherapy drugs and doses needed to be decreased during the course of the trial. One aspect of this trial focused on randomization of women with Her2/neu overexpression to 9 weeks of Herceptin or no Herceptin immediately following breast cancer surgery. The drug was given in conjunction with certain types of chemotherapy, but before radiation and chemotherapy regimens known to damage the heart. The journalist states the Herceptin was given "prior to chemotherapy", which is not completely accurate. There is an adequate mention of the study design and discussion of disease-free survival at 3 years follow-up. Good job putting the results into context of other trials, and into context of how this may or may not change providers' practice. The story could have better stated the limitations of analysis for such a small subgroup 116 in each arm. Appropriately discusses the percentage of women who are eligible for Herceptin due to overexpression of HER2/neu. The story would have been helped by some context for the risk these women face. As Herceptin is used earlier and earlier these women have less to gain because they have less risk to begin with. Relative risk reductions may be very high but the absolute is not as big. Sources in addition to study authors are cited. No mention that this trial was funded in part by pharmaceutical companies. Some study investigators also receive research funding drug companies. Other doctors cited express caution about the early results of Herceptin studies, so there is some balance to the piece. The women in this trial had undergone breast cancer surgery and those with ER+ tumors were taking Tamoxifen. This is not explicitly mentioned, only that treatment took place following surgery. Still OK. Herceptin is only FDA approved to treat advanced breast cancer, but is used in clinical trials in early-stage breast cancer. This is not mentioned in the story. Novel use of Herceptin for short-term treatment prior to anthracycline chemotherapy. No evidence that this story relies on a press release. Claim: Short stint of Herceptin holds promise for breast cancer
[EX A]: This story discusses the results of a recent study involving women with high-risk early breast cancer (node positive or >2cm, age younger than 66 there were 25 year olds on the trial). One aspect of this trial focused on the short-term use of Herceptin with chemotherapy. Women with overexpression of the HER2/neu gene, as measured by the CISH immunohistochemistry, were randomly assigned 9 weeks of Herceptin or no Herceptin immediately following breast cancer surgery and in conjunction with certain types of chemotherapy. This regimen of treatment differed from other trials in which Herceptin was given for 12 months following chemotherapy. In this study, the drug was given in conjunction with certain types of chemotherapy, but before radiation and chemotherapy regimens known to damage the heart. The journalist states the Herceptin was given "prior to chemotherapy," which is not completely accurate. Herceptin is only FDA approved to treat advanced breast cancer, but it is used in clinical trials in early-stage breast cancer. However, this is not mentioned in the story. There is adequate discussion of the study design and reporting of disease-free survival at 3 years follow-up. There was little discussion in the piece of the side effects of chemotherapy as reported in the trial, but the addition of Herceptin was the main focus of the story. While the journalist provides quantitative benefit of 9 weeks of Herceptin vs. no Herceptin, and notes no cardiac failure in the Herceptin group, the follow-up period of 3 years may not be long-enough to determine the effects of chemotherapy and Herceptin on the heart. Overall, the journalist did a good job describing the randomization, as well as putting the results into context of other trials, and into context of how this may or may not change providers' practice. The story could have better stated the limitations of analysis for such a small subgroup (116 in each arm). The small sample randomized to Herceptin certainly warrants more study, and although the relative benefits were large, these women still had fairly good recurrence free survival 80% w/o and 90% with so although it looks like that will translate to overall survival. The question for women with overexpression of the HER/neu gene is: How much do you want to do to avoid recurrence? Sources in addition to the study investigators are cited, which provides some balance to the piece, however, there is no mention that the trial was funded in part by pharmaceutical companies. Some study investigators also receive research funding from drug companies.

[EX Q]: Paragraph: Pfizer shares were up nearly 4 percent on positive findings for the oral treatment, called palbociclib, one of the company's most important experimental drugs that some analysts believe could eventually claim annual sales of more than $5 billion, if approved. The trial tested the pill in post-menopausal patients with locally advanced or newly diagnosed breast cancer that had spread to other parts of the body. "We are delighted with the final data," Pfizer said in a release, adding the company will discuss the successful data on progression-free survival with the U.S. Food and Drug Administration "to determine next steps" for palbociclib. A secondary goal of the study is to determine whether palbociclib can prolong overall survival. But Pfizer spokeswoman Sally Beatty said the company does not yet have such data, because it takes longer periods to follow patients and gauge survival trends. Although Pfizer is conducting two larger late-stage trials of palbociclib, ISI Group analyst Mark Schoenebaum noted the company has previously said it might discuss with the FDA the potential to seek approval of the medicine based upon mid-stage trial data, if the data warranted. Palbociclib, which blocks enzymes known as cyclin-dependent kinases (CDKs) 4 and 6, was taken in combination with a standard treatment called letrozole among women who were estrogen receptor positive - meaning tumors grow in response to estrogen - and HER2-negative, meaning that the HER2 protein is not causing the cancer. Such patients make up about 60 percent of advanced breast cancer cases. Letrozole is the chemical name of Femara, a Novartis AG drug that belongs to a class of treatments called aromatase inhibitors that block production of estrogen. Pfizer on Monday did not present detailed data from the trial results, saying they would be presented at a scientific meeting in San Diego in April. The success of the trial, called Paloma-1, follows highly favorable interim data that Pfizer unveiled in December 2012. At that point in the study, those taking both palbociclib and letrozole went an average of 26.1 months before tumors worsened. That compared with 7.5 months for those taking letrozole, but not palbociclib. The 18.6-month difference was considered statistically significant. Side effects from palbociclib were similar to those previously reported, Pfizer said on Monday. The earlier interim results had shown that patients taking the drug combination experienced anemia, fatigue and neutropenia - a decline in white blood cells called neutrophils that can put patients at higher risk of infection. Palbociclib was designated a "breakthrough" drug by the FDA last April based on initial data from the trial. The FDA grants "breakthrough" status to drugs that may offer substantial improvement over existing treatments for serious or life-threatening diseases. The status helps to speed up the approval process. Pfizer has started two late-stage trials of the drug - Paloma-2 and Paloma-3 - in patients with advanced breast cancer. Paloma-2 will test the same drug combination, palbociclib and letrozole, as an initial treatment for breast cancer. Paloma-3 will evaluate palbociclib in combination with another hormone therapy, fulvestrant, in women whose cancer has progressed after hormonal therapy. The drug, sold under the brand name Faslodex by AstraZeneca Plc, is called an estrogen receptor antagonist. Companies trying to develop treatments similar to palbociclib include Novartis and Eli Lilly & Co. Breast cancer killed more than 508,000 women worldwide in 2011, according to the World Health Organization. Pfizer shares were up 3.7 percent at $31.53 on Monday morning on the New York Stock Exchange. Claim: Pfizer breast cancer drug succeeds in mid-stage trial.
[EX A]: Pfizer Inc's experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study's primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease.

[EX Q]: Paragraph: Scott Wood, white Kansas City Deputy, shot 7x by 3 black men & no mention made of race. Had roles been reversed? PLEASE SHARE! This is deputy Scott Wood of the Wyandotte County Sheriff's Office (Kansas City, Kansas). Deputy Wood had finished his shift and stopped at a 7-Eleven before going home. While at the counter, Deputy Wood was attacked from behind by three armed black men. They shot Deputy Wood seven times and robbed him and the store. There is no national media coverage of this brutal attack on an unsuspecting person. There is no news show crying outrage over this or even mentioning it. I think people should know how dangerous it is for Police and how unfair they are treated by the news to boost ratings and sell ads. Deputy Wood is still alive and fighting for his life in stable but critical condition. He is a better man than the three that attacked him. Wishing him a speedy recovery. A fundraising page has been created by the WyCo Sheriff's office to help the Wood family In the very early morning hours of 4 March 2015, off-duty Wyandotte County, Kansas Deputy Scott Wood was shot at a local 7-11 store. On 5 March 2015, WDAF-TV in Kansas City reported that Deputy Wood called in the crime (then in-progress) and subsequently reported he sustained gunshot wounds before he was shot again in the face: Deputy Wood's shift had just concluded at about 1 a.m. on Wednesday when he stopped by the 7-Eleven off of Shawnee Drive and I-635 when three men entered the store. Investigators say the men were believed to be involved in two other convenience store robberies and were planning to rob the 7-Eleven when they hit a clerk with a gun and shot the deputy. Deputy Wood fell to the ground, but was able to use a portable radio to call in "officer down" before he was shot once more in the face. Sheriff Ash said the suspects then robbed the store, robbed the deputy and fled the scene, sparking a manhunt. On 9 March 2015, the same station reported that three men in custody were under investigation in relation to the ambush that seriously injured Deputy Wood. In other articles, the suspects were described as "multiple persons of interest" in the incident during which Wood was shot: All three men, who before the robbery were already convicted felons, have been charged with some very serious crimes stemming from the incident, which police say took place the same night Wyandotte County Sheriff's Deputy Scott Wood was shot multiple times, critically injuring him. Charles Bowser was first to face the judge in the courtroom. Next was Dyron King and then King's cousin, Cecil Meggerson. Each man was charged with two counts of aggravated robbery, conspiracy and criminal possession of a firearm. Deputy Scott Wood's shooting and recovery were reported extensively in the news media, although the coverage was primarily local in nature. According to the FBI's Law Enforcement Officers Killed and Assaulted (LEOKA) tally, about 50,000 police officers are assaulted in the line of duty each year, with about 250 of them suffering injuries from assaults with firearms. Obviously all of these incidents involving the shooting of police, as unfortunate and tragic as they may be, don't make the national news. In Deputy Wood's case, there were no additional reported factors present that served to propel his case into the national sphere: the shooting was not fatal, the assault on him was not premeditated (he was coincidentally present when armed robbers entered a convenience store), and there was no indication that he was targeted due to his race. Thankfully, Deputy Wood was not killed in the assault and recovered from the brutal crime relatively speedily. By 13 March 2015 Wood (who suffered seven gunshot injuries) had made remarkable strides and was breathing and walking on his own, a factor which (sadly, some might reflect) made his shooting a somewhat less noteworthy story outside of Wyandotte County by news media standards: Another factor that may have played into less extensive news coverage is that Wood's assailants had not been officially identified at the time the above-reproduced meme began to circulate, and no arrests had been made in the shooting. It wasn't even clear if police had determined that the men described as persons of interest in early media reports were in fact connected with the crime. By April 2018, however, three men had been arrested, convicted, and sentenced for their part in the attempted killing of Deputy Wood: Charles Bowser was sentenced to life plus 447 months in prison on [20 April 2018], according to the Wyandotte County District Attorney's Office. Bowser, 21, was found guilty by a Wyandotte County jury [in May 2017] for attempting to kill Scott Wood in March 2015. The deputy was inside a Kansas City, Kan., convenience store when three armed robbers burst in. The two others involved, Cecil Meggerson, 36, and Dyron King, 25, were also convicted. They were sentenced to life in prison in 2016 and each received an additional 37 years for other convictions in the case. Wood testified at an earlier trial that he was in uniform when he stopped on his way home from work at a 7-Eleven on Shawnee Drive near Interstate 635. The deputy was talking to the store clerk and had his back to the door when three armed men burst in and forced him to the ground at gunpoint. Both Wood and the clerk were pistol-whipped. One of the gunmen took Wood's handgun before they began firing shots at him. One bullet shattered his jaw. Another hit him in the shoulder, and five more struck him in the chest and abdomen. "When I look into the mirror at my scars and wounds, I am reminded of what these men tried to take away from me," Wood said in his statement. "Not only did they try to take my life away from me, they also tried to take away from me the chance to spend one more day with my wife and son." Claim: Deputy Scott Wood was shot by black convenience store robbers, and the incident was not widely reported in the national media.
[EX A]:
Deputy Scott Wood was shot when three black men attempted to rob a convenience store in March 2015.